The estimated Net Worth of R Sanders Williams is at least $4.82 Milione dollars as of 6 February 2024. Robert Williams owns over 947 units of AMGEN stock worth over $2,679,438 and over the last 18 years he sold AMGN stock worth over $1,799,602. In addition, he makes $339,716 as Independent Director at AMGEN.
Robert has made over 30 trades of the AMGEN stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 947 units of AMGN stock worth $312,491 on 6 February 2024.
The largest trade he's ever made was exercising 6,292 units of AMGEN stock on 19 May 2011 worth over $477,814. On average, Robert trades about 384 units every 52 days since 2007. As of 6 February 2024 he still owns at least 8,120 units of AMGEN stock.
You can see the complete history of Robert Williams stock trades at the bottom of the page.
Dr. Robert Sanders Williams M.D. serves as Independent Director of the Company. Dr. Williams is the President Emeritus of Gladstone Institutes, a non-profit biomedical research enterprise, having served in this position since 2018, and was the Chief Executive Officer of Gladstone Foundation, a not-for-profit organization supporting the Gladstone Institutes during 2018. Dr. Williams has been a Professor of Medicine at the University of California, San Francisco since 2010, and Professor of Medicine at Duke University since 2018. Dr. Williams was both President of Gladstone Institutes and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, from 2010 to 2017. Prior to this, Dr. Williams served as Senior Vice Chancellor of the Duke University School of Medicine from 2008 to 2010 and Dean of the Duke University School of Medicine from 2001 to 2008. He was the founding Dean of the Duke-NUS Graduate Medical School, Singapore, from 2003 to 2008 and served on its Governing Board from 2003 to 2010. From 1990 to 2001, Dr. Williams was Chief of Cardiology and Director of the Ryburn Center for Molecular Cardiology at the University of Texas, Southwestern Medical Center. Dr. Williams has been a director of the Laboratory Corporation of America Holdings, a diagnostic technologies company, since 2007, serving on the Audit and Compensation Committees and chairing the Quality and Compliance Committee. Dr. Williams was a director of Bristol-Myers Squibb Company, a pharmaceutical company, from 2006 until 2013. Dr. Williams has served on the board of directors of the Gladstone Foundation, a non-profit institution that is distinct from Gladstone Institutes, since 2012 and on the board of directors of Exploratorium, a non-profit science museum and learning center located in San Francisco, from 2011 until 2018. Dr. Williams was elected to the National Academy of Medicine in 2002. Dr. Williams received his undergraduate degree from Princeton University and his doctorate from Duke University.
As the Independent Director of AMGEN, the total compensation of Robert Williams at AMGEN is $339,716. There are 16 executives at AMGEN getting paid more, with Robert Bradway having the highest compensation of $19,612,800.
Robert Williams is 71, he's been the Independent Director of AMGEN since 2014. There are 1 older and 24 younger executives at AMGEN. The oldest executive at AMGEN Inc. is Fred Hassan, 74, who is the Independent Director.
R's mailing address filed with the SEC is THE J. DAVID GLADSTONE INSTITUTES, OWENS STREET, SAN FRANCISCO, CA, 94158-2261.
Over the last 22 years, insiders at AMGEN have traded over $219,663,137 worth of AMGEN stock and bought 8,904 units worth $919,219 . The most active insiders traders include Robert Eckert, Kevin W Sharer e Ellen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of $8,732,261. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth $662,812.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
AMGEN executives and other stock owners filed with the SEC include: